Nuon Therapeutics Inc. Appoints Paulette Dillon, Chief Business Officer, and Tito Serafini, Chief Scientific Officer

Published: Jul 16, 2009

SAN MATEO, Calif.--(BUSINESS WIRE)--Nuon Therapeutics, Inc., a clinical stage, privately-held biopharmaceutical company focused on novel therapies for autoimmune and inflammatory diseases, today announced the appointments of Paulette Dillon to the position of chief business officer and Tito Serafini, Ph.D., to the position of chief scientific officer, both reporting to president and CEO Rodney Pearlman, Ph.D.

Back to news